Edoxaban for the prevention of stroke in patients with atrial fibrillation

References

• Kirchhof P, Benussi S, Kotecha D, et al. ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–2962.
   PubMed Web of Science ®Google Scholar
• Barrios V, Calderón A, Escobar C, et al. Patients with atrial fibrillation in a primary care setting: val-FAAP study. Rev Esp Cardiol. 2012;65(1):47–53.
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C, Bertomeu V, et al. Risk factor control in the hypertensive patients with chronic ischemic heart disease attended in cardiologic outpatient clinics. The CINHTIA study. Rev Clin Esp. 2008;208(8):400–404.
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Packer M, Desai AS, et al., PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004.
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C, Calderón A, et al. Use of antithrombotic therapy according to CHA2DS2-VASc score in patients with atrial fibrillation in primary care. Rev Esp Cardiol (Engl Ed). 2014;67(2):150–151.
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C, Prieto L, et al. Anticoagulation control in patients with nonvalvular atrial fibrillation attended at primary care centers in Spain: the PAULA study. Rev Esp Cardiol (Engl Ed). 2015;68(9):769–776.
   PubMed Web of Science ®Google Scholar
• Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Int Med. 2007;146(12):857–867.
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C. Implications of edoxaban in the prevention and treatment of thromboembolic complications in clinical practice. Future Cardiol. 2016;12(4):419–433.
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C. Edoxaban in the prevention and treatment of thromboembolic complications from a clinical point of view. Expert Rev Cardiovasc Ther. 2015;13(7):811–824.
   PubMed Web of Science ®Google Scholar
• Hsu JC, Freeman JV. Underuse of vitamin K antagonist and direct oral anticoagulants for stroke prevention in patients with atrial fibrillation: A contemporary review. Clin Pharmacol Ther. 2018;104(2):301–310.
   PubMed Web of Science ®Google Scholar
• Franco Moreno AI, Martín Díaz RM, García Navarro MJ. Direct oral anticoagulants: an update. Med Clin (Barc). 2018;151(5):198–206.
   PubMed Web of Science ®Google Scholar
• Steffel J, Verhamme P, Potpara TS, et al. The 2018 European heart rhythm association practical guide on the use of non-vitamin kantagonist oral anticoagulants in patients with atrial fibrillation: executive summary. Europace. 2018;20(8):1231–1242.
   PubMed Web of Science ®Google Scholar
• Alalwan AA, Voils SA, Hartzema AG. Trends in utilization of warfarin and direct oral anticoagulants in older adult patients with atrial fibrillation. Am J Health Syst Pharm. 2017;74(16):1237–1244.
   PubMed Web of Science ®Google Scholar
• Yu AYX, Malo S, Svenson LW, et al. Temporal trends in the use and comparative effectiveness of direct oral anticoagulant agents versus warfarin for nonvalvular atrial fibrillation: a Canadian population-based study. J Am Heart Assoc. 2017;6:11.
   Web of Science ®Google Scholar
• Marzec LN, Wang J, Shah ND, et al. Influence of Direct Oral Anticoagulants on Rates of Oral Anticoagulation for Atrial Fibrillation. J Am Coll Cardiol. 2017;69(20):2475–2484.
   PubMed Web of Science ®Google Scholar
• Hammwöhner M, Goette A. The safety of edoxaban for treating atrial fibrillation. Expert Opin Drug Saf. 2017;16(11):1295–1303.
   PubMed Web of Science ®Google Scholar
• Proietti M, Lip GY. Edoxaban in venous thromboembolism and stroke prevention: an appraisal. Vasc Health Risk Manag. 2016;12:45–51.
   PubMed Web of Science ®Google Scholar
• De Caterina R, Ageno W, Boriani G, et al. Edoxaban in atrial fibrillation and venous thromboembolism-ten key questions and answers: a practical guide. Adv Ther. 2017;34(3):620–637.
   PubMed Web of Science ®Google Scholar
• Weiss TW, Rohla M, Dieplinger B, et al. Edoxaban for stroke prevention in atrial fibrillation and treatment of venous thromboembolism: an expert position paper. Wien Med Wochenschr. 2018;168(5–6):133–143.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMA). Lixiana®, “Summary of Product Characteristics”. [Updated 2017 Jul 20]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002629/WC500189045.pdf
   Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al., ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–2104.
   PubMed Web of Science ®Google Scholar
• Duchin K, A D, Atiee GJ, et al. An open-label crossover study of the pharmacokinetics of the 60-mg edoxaban tablet crushed and administered either by a nasogastric tube or in apple puree in healthy adults. Clin Pharmacokinet. 2018;57(2):221–228.
   PubMed Web of Science ®Google Scholar
• Vandell AG, Lee J, Shi M, et al. An integrated pharmacokinetic/pharmacogenomic analysis of ABCB1 and SLCO1B1 polymorphisms on edoxaban exposure. Pharmacogenomics J. 2018;18(1):153–159.
   PubMed Web of Science ®Google Scholar
• Aspromonte N, Colivicchi F. Clinical relevance of pharmacokinetic and pharmacodynamic properties of edoxaban when treating patients with atrial fibrillation and heart failure. Expert Opin Drug Metab Toxicol. 2017;13(1):113–122.
   PubMed Web of Science ®Google Scholar
• Shimizu T, Tachibana M, Kimura T, et al. Population pharmacokinetics of edoxaban in Japanese atrial fibrillation patients with severe renal impairment. Clin Pharmacol Drug Dev. 2017;6(5):484–491.
   PubMed Web of Science ®Google Scholar
• Eisen A, Ruff CT. Edoxaban in patients with atrial fibrillation. Ther Adv Cardiovasc Dis. 2017;11(3):81–90.
   PubMedGoogle Scholar
• Parasrampuria DA, Truitt KE. Pharmacokinetics and pharmacodynamics of edoxaban, a non-vitamin K antagonist oral anticoagulant that inhibits clotting factor xa. Clin Pharmacokinet. 2016;55(6):641–655.
   PubMed Web of Science ®Google Scholar
• Stacy ZA, Call WB, Hartmann AP, et al. Edoxaban: a comprehensive review of the pharmacology and clinical data for the management of atrial fibrillation and venous thromboembolism. Cardiol Ther. 2016;5(1):1–18.
   PubMed Web of Science ®Google Scholar
• Parasrampuria DA, Kanamaru T, Connor A, et al. Evaluation of regional gastrointestinal absorption of edoxaban using the enterion capsule. J Clin Pharmacol. 2015;55(11):1286–1292.
   PubMed Web of Science ®Google Scholar
• Switzer MP, Wani P, Gosavi S, et al. Clinical pharmacology and role of edoxaban in contemporary antithrombotic therapy. Cardiovasc Hematol Agents Med Chem. 2015;13(2):98–104.
   PubMedGoogle Scholar
• Jönsson S, Simonsson US, Miller R, et al. Population pharmacokinetics of edoxaban and its main metabolite in a dedicated renal impairment study. J Clin Pharmacol. 2015;55(11):1268–1279.
   PubMed Web of Science ®Google Scholar
• Mendell J, Johnson L, Chen S. An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics. J Clin Pharmacol. 2015;55(12):1395–1405.
   PubMed Web of Science ®Google Scholar
• Parasrampuria DA, Marbury T, Matsushima N, et al. Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis. Thromb Haemost. 2015;113(4):719–727.
   PubMed Web of Science ®Google Scholar
• Mikkaichi T, Yoshigae Y, Masumoto H, et al. Edoxaban transport via P-glycoprotein is a key factor for the drug’s disposition. Drug Metab Dispos. 2014;42(4):520–528.
   PubMed Web of Science ®Google Scholar
• Mendell J, Zahir H, Matsushima N, et al. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs. 2013;13(5):331–342.
   PubMed Web of Science ®Google Scholar
• Mendell J, Tachibana M, Shi M, et al. Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers. J Clin Pharmacol. 2011;51(5):687–694.
   PubMed Web of Science ®Google Scholar
• Ingrasciotta Y, Crisafulli S, Pizzimenti V, et al. Pharmacokinetics of new oral anticoagulants: implications for use in routine care. Expert Opin Drug Metab Toxicol. 2018;14(10):1057–1069.
   PubMed Web of Science ®Google Scholar
• Weitz JI, Connolly SJ, Patel I, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010;104(3):633–641.
   PubMed Web of Science ®Google Scholar
• Yamashita T, Koretsune Y, Yasaka M, et al. Randomized, multicenter, warfarin-controlled phase II study of edoxaban in Japanese patients with non-valvular atrial fibrillation. Circ J. 2012;76(8):1840–1847.
   PubMed Web of Science ®Google Scholar
• Salazar DE, Mendell J, Kastrissios H, et al. Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation. Thromb Haemost. 2012;107(5):925–936.
   PubMed Web of Science ®Google Scholar
• Krekels EH, Niebecker R, Karlsson MO, et al. Population pharmacokinetics of edoxaban in patients with non-valvular atrial fibrillation in the ENGAGE AF-TIMI 48 study, a phase III clinical trial. Clin Pharmacokinet. 2016;55(9):1079–1090.
   PubMed Web of Science ®Google Scholar
• Yin OQ, Tetsuya K, Miller R. Edoxaban population pharmacokinetics and exposure-response analysis in patients with non-valvular atrial fibrillation. Eur J Clin Pharmacol. 2014;70(11):1339–1351.
   PubMed Web of Science ®Google Scholar
• Ruff CT, Giugliano RP, Antman EM, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the effective anticoagulation with factor Xa next generation in atrial fibrillation-thrombolysis in myocardial infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J. 2010;160(4):635–641.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891.
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med. 2011;365(11):981–992.
   PubMed Web of Science ®Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Association between edoxaban dose, concentration, anti-factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015;385(9984):2288–2295.
   PubMed Web of Science ®Google Scholar
• Eisen A, Ruff CT, Braunwald E, et al. Sudden cardiac death in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 trial. J Am Heart Assoc. 2016;5(7).
   Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Wiviott SD, et al. Mortality in patients with atrial fibrillation randomized to edoxaban or warfarin: insights from the ENGAGE AF-TIMI 48 trial. Am J Med. 2016;129(8):850–857.e2.
   PubMed Web of Science ®Google Scholar
• Link MS, Giugliano RP, Ruff CT, et al. Stroke and mortality risk in patients with various patterns of atrial fibrillation: results from the ENGAGE AF-TIMI 48 trial (Effective anticoagulation with factor Xa next generation in atrial fibrillation-thrombolysis in myocardial infarction 48). Circ Arrhythm Electrophysiol. 2017;10(1).
   Web of Science ®Google Scholar
• Rost NS, Giugliano RP, Ruff CT, et al. Outcomes with edoxaban versus warfarin in patients with previous cerebrovascular events: findings from ENGAGE AF-TIMI 48 (Effective anticoagulation with factor Xa next generation in atrial fibrillation-thrombolysis in myocardial infarction 48). Stroke. 2016;47(8):2075–2082.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Rost NS, et al. Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: effective anticoagulation with factor Xa next generation in atrial fibrillation-thrombolysis in myocardial infarction 48. Stroke. 2014;45(8):2372–2378.
   PubMed Web of Science ®Google Scholar
• De Groot JR, Ruff CT, Murphy SA, et al. Edoxaban versus warfarin in patients with atrial fibrillation in relation to stroke risk. A subanalysis of the ENGAGE AF-TIMI 48 study. Eur Heart J. 2017;38(Supplement):1215. A5719.
   PubMedGoogle Scholar
• Wang K, Li H, Kwong WJ, et al. Impact of spontaneous extracranial bleeding events on health state utility in patients with atrial fibrillation: results from the ENGAGE AF-TIMI 48 trial. J Am Heart Assoc. 2017;6(8).
   Web of Science ®Google Scholar
• Bergmark BA, Stehouwer A, Wiviott SD, et al. Comparison of events across definitions of major bleeding in the engage AF-TIMI 48 trial. Circulation. 2017;136(Suppl 1):A15134.
   Google Scholar
• Kato ET, Giugliano RP, Ruff CT, et al. Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. J Am Heart Assoc. 2016;5(5):e003432.
   PubMed Web of Science ®Google Scholar
• Steffel J, Giugliano RP, Braunwald E, et al. Edoxaban versus warfarin in atrial fibrillation patients at risk of falling: ENGAGE AF-TIMI 48 analysis. J Am Coll Cardiol. 2016;68(11):1169–1178.
   PubMed Web of Science ®Google Scholar
• Bohula EA, Giugliano RP, Ruff CT, et al. Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 trial. Circulation. 2016;134(1):24–36.
   PubMed Web of Science ®Google Scholar
• Qamar A, Antman EA, Ruff CT, et al. Efficacy and safety of edoxaban vs. warfarin in patients with atrial fibrillation and hepatic disease: insights from the ENGAGE AF-TIMI 48 trial. Eur Heart J. 2017;38(Supplement):766–767.A3586.
   Google Scholar
• Zelniker TA, Ruff CT, Wiviott SD, et al. High-dose edoxaban regimen versus warfarin in patients with atrial fibrillation and established coronary artery disease: insights from the ENGAGE AF-TIMI 48 trial. Circulation. 2017;136(Suppl 1):A17950.
   Google Scholar
• Magnani G, Giugliano RP, Ruff CT, et al. Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48. Eur J Heart Fail. 2016;18(9):1153–1161.
   PubMed Web of Science ®Google Scholar
• De Caterina R, Renda G, Carnicelli AP, et al. Valvular heart disease patients on edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. J Am Coll Cardiol. 2017;69(11):1372–1382.
   PubMed Web of Science ®Google Scholar
• Carnicelli AP, De Caterina R, Halperin JL, et al. Edoxaban for the prevention of thromboembolism in patients with atrial fibrillation and bioprosthetic valves. Circulation 2017;135(13):1273–1275.
   PubMed Web of Science ®Google Scholar
• Fanola C, Ruff C, Murphy S, et al. Efficacy and safety of edoxaban in patients with atrial fibrillation and active malignancy: an analysis of ENGAGE AF – TIMI 48 randomized clinical trial. J Am Coll Cardiol. 2017;69(11 Supplement):325.
   PubMed Web of Science ®Google Scholar
• Steffel J, Ruff CT, Hamershock RA, et al. First experience with edoxaban and atrial fibrillation ablation - insights from the ENGAGE AF-TIMI 48 trial. Int J Cardiol. 2017;244:192–195.
   PubMed Web of Science ®Google Scholar
• Plitt A, Ezekowitz MD, De Caterina R, et al. Cardioversion of atrial fibrillation in ENGAGE AF-TIMI 48. Clin Cardiol. 2016;39(6):345–346.
   PubMed Web of Science ®Google Scholar
• Goette A, Merino JL, Ezekowitz MD, et al. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet. 2016;388(10055):1995–2003.
   PubMed Web of Science ®Google Scholar
• O‘Donoghue ML, Ruff CT, Giugliano RP, et al. Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation. Eur Heart J. 2015;36(23):1470–1477.
   PubMed Web of Science ®Google Scholar
• Xu H, Ruff CT, Giugliano RP, et al. Concomitant use of single antiplatelet therapy with edoxaban or warfarin in patients with atrial fibrillation: analysis from the ENGAGE AF-TIMI48 trial. J Am Heart Assoc. 2016;5(2).
   Web of Science ®Google Scholar
• Steffel J, Giugliano RP, Braunwald E, et al. Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial. Eur Heart J. 2015;36(33):2239–2245.
   PubMed Web of Science ®Google Scholar
• Cavallari I, Ruff CT, Nordio F, et al. Clinical events after interruption of anticoagulation in patients with atrial fibrillation: an analysis from the ENGAGE AF-TIMI 48 trial. Int J Cardiol. 2018;257:102–107.
   PubMed Web of Science ®Google Scholar
• Tanislav C, Milde S, Schwartzkopff S, et al. Baseline characteristics in stroke patients with atrial fibrillation: clinical trials versus clinical practice. BMC Res Notes. 2015;8:262.
   PubMedGoogle Scholar
• Camm AJ, Fox KAA, Peterson E. Challenges in comparing the non-vitamin K antagonist oral anticoagulants for atrial fibrillation-related stroke prevention. Europace. 2018;20(1):1–11.
   PubMed Web of Science ®Google Scholar
• Pottegård A, Grove EL, Hellfritzsch M. Use of direct oral anticoagulants in the first year after market entry of edoxaban: a Danish nationwide drug utilization study. Pharmacoepidemiol Drug Saf. 2018;27(2):174–181.
   PubMed Web of Science ®Google Scholar
• Blann AD, Banerjee A, Lane DA, et al. Net clinical benefit of edoxaban versus no treatment in a ‘real world‘ atrial fibrillation population: A modelling analysis based on a nationwide cohort study. Int J Cardiol. 2015;201:693–698.
   PubMed Web of Science ®Google Scholar
• Sezai A, Osaka S, Yaoita H, et al. Safety of the direct oral anticoagulant edoxaban for atrial fibrillation after cardiac surgery: pilot Study. J Atr Fibrillation. 2016;9(3):1456.
   PubMedGoogle Scholar
• Kottmaier M, Bourier F, Pausch H, et al. Safety of uninterrupted periprocedural edoxaban versus phenprocoumon for patients who underwent left atrial catheter ablation procedures. Am J Cardiol. 2018;121(4):445–449.
   PubMed Web of Science ®Google Scholar
• Yamaji H, Murakami T, Hina K, et al. Differences in activated clotting time and initial heparin dosage during atrial fibrillation ablation for patients with edoxaban compared with warfarin. J Cardiovasc Electrophysiol. 2018;29(6):835–843.
   PubMed Web of Science ®Google Scholar
• Masjuán J, Álvarez-Sabín J, Blanco M, et al. Current management of antithrombotic treatment in patients with non valvular atrial fibrillation and prior history of stroke or transient ischemic attack. Rev Neurol. 2014;59(1):25–36.
   PubMed Web of Science ®Google Scholar
• Masjuan J, DeFelipe A. Secondary prevention in non-valvular atrial fibrillation patients: a practical approach with edoxaban. Int J Neurosci. 2017;127(8):716–725.
   PubMed Web of Science ®Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–962.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151.
   PubMed Web of Science ®Google Scholar
• Ageno W, Beyer-Westendorf J, Rubboli A. Once- versus twice-daily direct oral anticoagulants in non-valvular atrial fibrillation. Expert Opin Pharmacother. 2017;18(13):1325–1332.
   PubMed Web of Science ®Google Scholar
• Lu G, Pine P, Leeds JM, et al. Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model. PLoS One. 2018;13(3):e0195122.
   PubMed Web of Science ®Google Scholar
• Magnuson EA, Vilain K, Wang K, et al. Cost-effectiveness of edoxaban vs warfarin in patients with atrial fibrillation based on results of the ENGAGE AF-TIMI 48 trial. Am Heart J. 2015;170(6):1140–1150.
   PubMed Web of Science ®Google Scholar
• Vilain KA, Yang MC, Hui Tan EC, et al. Cost-effectiveness of edoxaban vs. warfarin in patients with atrial fibrillation based on results of the ENGAGE AF - TIMI 48 trial: Taiwanese perspective. Value Health Reg Issues. 2017;12:74–83.
   PubMedGoogle Scholar
• Miller JD, Ye X, Lenhart GM, et al. Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US. Clinicoecon Outcomes Res. 2016;8:215–226.
   PubMed Web of Science ®Google Scholar
• Rognoni C, Marchetti M, Quaglini S, et al. Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis. J Thromb Thrombolysis. 2015;39(2):149–154.
   PubMed Web of Science ®Google Scholar
• Lekuona I, Anguita M, Zamorano JL, et al. Is edoxaban cost-effective for non-valvular atrial fibrillation patients treated with vitamin K antagonists in Spain? Value Health. 2015;18(7):A392.
   PubMed Web of Science ®Google Scholar
• Nguyen E, Egri F, Mearns ES, et al. Cost-effectiveness of high-dose edoxaban compared with adjusted-dose warfarin for stroke prevention in non-valvular atrial fibrillation patients. Pharmacotherapy. 2016;36(5):488–495.
   PubMed Web of Science ®Google Scholar
• Okumura K, Lip GYH, Akao M, et al. Edoxaban for the management of elderly Japanese patients with atrial fibrillation ineligible for standard oral anticoagulant therapies: rationale and design of the ELDERCARE-AF study. Am Heart J. 2017;194:99–106.
   PubMed Web of Science ®Google Scholar
• Vranckx P, Lewalter T, Valgimigli M, et al. Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: rationale and design of the ENTRUST-AF PCI trial. Am Heart J. 2018;196:105–112.
   PubMed Web of Science ®Google Scholar
• De Caterina R, Kelly P, Monteiro P, et al. Design and rationale of the edoxaban treatment in routine clinical practice for patients with atrial fibrillation in Europe (ETNA-AF-Europe) study. J Cardiovasc Med (Hagerstown). 2019;20(2):97–104.
   PubMed Web of Science ®Google Scholar